ISSN: Coming soon...

MSD Journal of Cardiology and Cardiovascular Medicine

Letter to Editor       Open Access      Peer-Reviewed

Remdesivir and Cardiovascular Safety Issues: Beyond the Treatment of COVID-19.

Fernando Mesta1 and Livan Delgado-Roche2*

Letter to Editor

Dear Editor

Remdesivir is an adenosine nucleotide prodrug that is metabolized to the pharmacologically active nucleoside triphosphate metabolite after being distributed into cells. Th e drug acts as an adenosine triphosphate analog and competes for incorporation into RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase, resulting in delayed chain termination during viral RNA replication [1]. Remdesivir effectively inhibited SARS-CoV-2 infected Vero cells in vitro study [2]. Moreover, remdesivir was found to be a potent inhibitor of SARSCoV- 2 replication in human nasal and bronchial airway epithelial cells [3]. These outcomes encouraged the compassionate use remdesivir in patients with SARS-CoV-2 infection (COVID-19), in the absence of any effective treatment. The clinical assessment started with a cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, in which clinical improvement was observed in 36 of 53 patients (68%) [4].

Thereafter er, the first double-blind, placebocontrolled, randomized trial conducted with remdesivir versus placebo (n=236) in severe COVID-19 patients, Wang and coworkers found no significant difference in the primary outcome of time to clinical improvement within 28-days either in intention-to-treat analysis (median 21 days in remdesivir vs. 23 days in placebo arm; HR 1.23; 95%CI, 0.87 to 1.75) or in the per-protocol analysis (median 21 days in remdesivir vs. 23 days in placebo arm; HR 1.27, 95%CI; 0.89 to 1.80) [5]. As of 29 April 2020, preliminary results from the Adaptive COVID-19 Treatment Trial (ACTT) was communicated.

Th is was a multicenter, adaptive, randomized double-blind controlled trial aimed to evaluate the safety and effi cacy of remdesivir for the treatment of non-severe COVID-19 (n=800). Th e study showed a signifi cant “positive eff ect” in diminishing time to recovery from 15 days to 11 days. However, the mortality rate of remdesivir vs placebo (8% vs 11%) was not statistically signifi cant [6]. In the other face: the safety of remdesivir. Serious adverse events included acute kidney injury, septic shock and multiorgan failure have been reported. In addition, hypotension, cardiac arrest, hyponatremia, atrial fi brillation, hypersensitivity including infusionrelated and anaphylactic reactions [1]. Wang et al. reported similar proportion of adverse events in remdesivir (66%) and control arm (64%).

However, serious adverse events reported in 18% vs. 26% in remdesivir compared with controls, respectively. A high proportion of patients from the remdesivir group discontinued the treatment (12%) compared to the control arm (5%), either because of adverse events or serious adverse events [5]. On the other hand, in SIMPLE clinical trial, grade 3 or higher liver enzyme elevations occurred in 7.3% of patients, while 5% in 5-days arm and 10% in 10-days arm had to withdraw from remdesivir due to severe adverse events [7]. Until now, the cardiovascular safety of remdesivir is unclear, as well the potential underlying mechanisms. COVID-19 itself has been associated with cardiovascular damage, meanwhile cardiovascular risk factors may be associated with poor outcome in COVID-19 patients [8]. Th erefore, post-marketing surveillance programs focused on the risk/benefi t balance of remdesivir is of major relevance.